Ozempic jabs ‘significantly improve’ fat loss and blood sugar levels for up to three years, study suggests
FAT jabs can help people with type 2 diabetes lose weight and control their blood sugar for up to three years, a study has found.
Semaglutide — also known as Wegovy and Ozempic — can help “significantly improve” the condition in the long term, Israeli researchers found.
Professor Avraham Karasik, of Maccabi Health Services, said: “Our analysis found a clinically relevant improvement in blood sugar control and weight loss, comparable with that seen in randomised trials.
“Importantly, these effects were sustained for up to three years, supporting the use of once weekly semaglutide for the long-term management of type 2 diabetes.”
More than five million Brits are thought to be living with diabetes, with cases doubling in the last 15 years.
The NHS spends at least £10billion a year on the disease — around 10 per cent of its entire budget.
It causes blood sugar levels to become too high because of problems with how your body produces the hormone insulin, which breaks down glucose.
The National Institute for Care and Excellence (Nice) recommends the use of Ozempic to manage type 2 diabetes in England.
It also approved the use of Wegovy to aid weight loss on the NHS in England earlier this year, with its guidance recommending it should be used for a maximum of two years.
Previous trials have shown semaglutide can help patients lose up to 15 per cent of the body weight in one year.
The latest study, presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Hamburg, looked at longer-term data.
Researchers analysed data on the use of semaglutide in 200,000 patients from the Maccabi diabetes registry.
They found 23,442 eligible patients who used at least one prescription for semaglutide jabs between August 2019 and December 2022 and had one blood sugar control measurement (HbA1c) 12 months before and six months after starting treatment.
Before being prescribed semaglutide, 30 per cent of patients were treated with insulin and 31 per cent were treated with another drug from the weight-loss jab family, known as glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Six months after starting on semaglutide, patients lowered their HbA1c by an average of 0.77 per cent (from 7.6 per cent to 6.8 per cent) and reduced their body weight by an average of 4.7 kg (from 94.1 kg to 89.7 kg).
The reduction in weight and blood sugar was more pronounced in those who had never taken semaglutide.
A follow-up after two years found HbA1c and body weight fell by an average of 0.76 per cent and 6.0kg respectively, while at three years they were down by 0.43 per cent and 5.8kg.
The study was funded by Wegovy and Ozempic manufacturer Novo Nordisk.
Professor Karasik said: “In this large real-world study, we were able to show durable reductions in HbA1c and body weight with emphasis on drug adherence.
“Data are in line with results in randomised controlled trials and show the long-term stable benefit of once-weekly semaglutide.”
In August, Novo Nordisk published the findings of its own five-year study on Wegovy, known as the Select trial.
It found use of the drug can slash the risk of a heart attack or stroke in obese people by a fifth.
The study included 17,604 adults over the age of 45 from across 41 countries, each with a BMI of more than 27 and established cardiovascular disease, with no history of diabetes.
Wegovy officially launched in the UK last month and is prescribed to patients with a BMI of more than 30 – or 27 in the presence of other comorbidities – via specialist NHS services.
About 50,000 eligible patients are expected to benefit.
The launch followed the announcement of a £40million pilot by the Government in June to expand the use of weight-loss jabs in a bid to tackle obesity.
Prime Minister Rishi Sunak said using the latest drugs to support people in losing weight “will be a game-changer”.